Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Choi

Internal Medicine Lansing, MI Doctor of Osteopathy

NPI 1063907947 CMS profile 5051933

1215 E Michigan Ave, Lansing, MI 48912

Open in the dashboard

General payments

$7,447

230 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Choi of Lansing, MI is reported in the CMS Open Payments database as having received $7,447 across 230 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,141 60
2024 General $1,172 56
2023 General $1,266 67
2022 General $632 32
2021 General $151 10
2020 General $40 2
2019 General $46 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Choi
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to James Choi were reported at $4,141. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year James Choi Internal Medicine median Middle half National median
2019 $46 $159 $48–$570 $163
2020 $40 $119 $33–$402 $114
2021 $151 $135 $37–$521 $132
2022 $632 $141 $42–$496 $149
2023 $1,266 $149 $45–$519 $160
2024 $1,172 $154 $47–$537 $164
2025 $4,141 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $3,005 11 payments
  2. AstraZeneca Pharmaceuticals LP $1,215 63 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $630 29 payments
  4. GlaxoSmithKline, LLC. $444 28 payments
  5. Grifols USA, LLC $257 14 payments
  6. Regeneron Healthcare Solutions, Inc. $233 12 payments
  7. Mylan Specialty L.P. $202 9 payments
  8. Sanofi-Aventis U.S. LLC $183 2 payments
  9. Jazz Pharmaceuticals Inc. $121 4 payments
  10. Insmed, Inc. $116 6 payments
  11. Other $1,041 52 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,470 224 payments
  2. Education $2,763 4 payments
  3. Travel and Lodging $215 2 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $3,005 11 payments
  2. FASENRA $607 26 payments
  3. TEZSPIRE $545 21 payments
  4. OFEV $333 16 payments
  5. SPIRIVA RESPIMAT $297 12 payments
  6. DUPIXENT $269 6 payments
  7. AIRSUPRA $267 9 payments
  8. YUPELRI $241 11 payments
  9. Prolastin-C Liquid $239 13 payments
  10. BREZTRI $226 10 payments
  11. Other $2,404 124 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

305

Median for Internal Medicine: 777

Drug cost

$176,056

Median for Internal Medicine: $73,373

Branded share of claims

83%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 53 $61,990
Nucala Mepolizumab Brand 12 $44,356
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 37 $27,050
Spiriva Respimat Tiotropium Bromide Brand 21 $13,470
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 17 $8,717
Advair Hfa Fluticasone Propion/Salmeterol Brand 12 $7,189
Breo Ellipta Fluticasone/Vilanterol Brand 11 $5,048
Albuterol Sulfate Hfa Albuterol Sulfate Brand 79 $3,592
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 11 $3,470
Azithromycin Generic 19 $649

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • SANOFI-AVENTIS U.S. LLC $90
  • GENZYME CORPORATION $52
  • Regeneron Healthcare Solutions, Inc. $44
$187 — —
Prolastin-C Liquid
  • Grifols USA, LLC $173
$173 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $132
$132 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $121
$121 — —
NUCALA
  • GlaxoSmithKline, LLC. $85
$85 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

230 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record